Biorad QX200 droplet digital PCR system
Active Purchase Order Awarded Last action
- Contract number
- 75F40126P00099
- Awardee
-
Bio-Rad Laboratories, Inc. UEI SSHPDYFGN7J9 Part of Bio-Rad Laboratories, Inc.
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $38,931
Award facts
- Opportunity
-
- BioRad QX200 Droplet Digital PCR System Solicitation · 75F40126Q00195 · Posted Jun 1, 2026
- Contract value 82% obligated
-
- $38,930.93 Current, with exercised options
- $47,593.48 Potential, with all options
- Completion date 13% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6630 Chemical Analysis Instruments
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Rodeo, CA 94547, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration awarded a purchase order to Bio-Rad Laboratories, Inc. for one Bio-Rad QX200 Droplet Digital PCR System valued at $47,593.48, effective July 10, 2026, with ultimate completion by August 10, 2028.
The procurement is a brand-name restricted acquisition under FAR 11.105; the QX200 is required for compatibility with FDA's existing validated reverse transcription droplet digital PCR methods and assay development activities. The system includes the manual droplet generator, droplet reader, computer, software, installation, training, initial operational verification, and one-year manufacturer warranty. The system must process up to 96 samples per run with 2–3 hour completion times and require no more than 5 microliters of sample input per analysis. Delivery occurs within 30 calendar days of award to FDA's facility in Laurel, Maryland. Performance of the contract is at Bio-Rad's manufacturing location in Rodeo, California. The base performance period runs July 1, 2026 through June 30, 2027, with an optional extension through June 30, 2028. The originating solicitation was posted June 1, 2026, with quotations due June 8, 2026.
Quick answers
Who was awarded contract 75F40126P00099?
75F40126P00099 was awarded to Bio-Rad Laboratories, Inc. by Food and Drug Administration (Department of Health and Human Services) on July 10, 2026.
How much is contract 75F40126P00099 worth?
The government has obligated $38,931 on 75F40126P00099. Its potential value, with all options, is $47,593.
Was contract 75F40126P00099 competed?
The extent of competition for 75F40126P00099 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award